Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised €11M Series A (Jan 2026). FDA-cleared in 2025. Detects 96%+ of congenital heart defects in prenatal ultrasound. Distributed via GE HealthCare Voluson platform.
BrightHeart is a medical AI company developing prenatal diagnostic tools for detecting congenital heart defects (CHD) — the most common birth defect globally — through standard obstetric ultrasound. The company raised €11 million ($12 million) in Series A financing in January 2026 and achieved five FDA clearances in 2025 ahead of US commercial launch, with distribution through GE HealthCare's Voluson ultrasound platform.
Adept AI raised $415M to pioneer computer-use AI agents; its core research and agent team moved to Amazon in 2024 in a landmark talent acquisition while the company continues developing ACT-1 for enterprise automation.
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and executing multi-step workflows in any application. Its ACT-1 model demonstrated the ability to control web browsers and desktop applications through natural language instructions, pioneering the computer-use agent paradigm that Anthropic later commercialized with Claude's computer use feature.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.